Eric J. Lehrer

Sep 30, 2024 | mdpi.com | Lauren Webb |Anna F. Thomsen |Eric J. Lehrer |Allison R. Valerius

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Feb 5, 2024 | advancesradonc.org | Alexandra Hotca |Kunal Sindhu |Eric J. Lehrer |William Hartsell

1. Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6). 10.1007/s12328-020-01237-x2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. https://doi.org/10.3322/caac.217633. Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.

Jan 11, 2024 | redjournal.org | Eric J. Lehrer |Daniel M. Trifiletti |Simon Lo |Kristin J Redmond

ABSTRACT There is limited data available on clinical outcomes following stereotactic body radiation therapy (SBRT) for non-spinal bone metastases. We performed a systematic review and meta-analysis to characterize local control (LC), overall survival (OS), pain response rates, and toxicity following SBRT. Primary outcomes were 1-year LC, incidences of acute and late Grade 3-5 toxicities, and overall pain response rate at 3 months. The secondary outcome was 1-year OS.

Dec 8, 2023 | advancesradonc.org | Kristin Hsieh |Alexandra Hotca |Daniel Dickstein |Eric J. Lehrer

1Dickstein DR, Egerman M, Monrose E, et al. Treatment tolerability and outcomes in elderly patients with head and neck cancer. Head Neck. 2021;43(3):858-873. doi:10.1002/hed.265482Aupérin A. Epidemiology of head and neck cancers: an update. Curr Opin Oncol. 2020;32(3):178-186. doi:10.1097/CCO.00000000000006293Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669-683.

Jun 6, 2023 | mdpi.com | Kristin Hsieh |Daniel Dickstein |Eric J. Lehrer |Juliana Runnels

Abstract:The emergence of immune checkpoint inhibitors (ICIs) as a pillar of cancer treatment has emphasized the immune system’s integral role in tumor control and progression through cancer immune surveillance. ICIs are being investigated and incorporated into the treatment paradigm for lung cancers across stages and histology.